Breaking Finance News

Novavax, Inc. (NASDAQ:NVAX) has been downgraded to Neutral in a statement by Ladenburg Thalmann earlier today.

Ladenburg Thalmann has downgraded Novavax, Inc.(NASDAQ:NVAX) to Neutral in a statement released on 9/16/2016.

Previously on Tuesday August 23 2016, Vetr Inc. released a statement for Novavax, Inc.(NASDAQ:NVAX) raised the target price from $0.00 to $8.66. At the time, this indicated a possible upside of 0.17%.

Only yesterday Novavax, Inc. (NASDAQ:NVAX) traded 0.36% higher at $8.34. The company’s 50-day moving average is $7.35 and its two hundred day moving average is $6.24. With the last close up 33.70% relative to the 200-day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. Trading volume was was up over the average, with 25,965,663 shares of NVAX changing hands over the typical 5,016,980 shares..

See Graph Below:

Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. has a 52 week low of $4.08 and a 52 week high of $10.70 . Novavax, Inc.’s market cap is presently $0.0.

Also covering Novavax, Inc.’s target price, a total of 8 firms have issued a research note on the stock. The consensus target is $15.39 with five firms rating the company a strong buy, three firms rating the company a buy, 0 firms rating the stock a hold, 0 rating the stock to underperform, and finally 0 brokeragesrating the stock as sell.

General Company Details For Novavax, Inc. (NASDAQ:NVAX)

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, and including Middle East respiratory syndrome (MERS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *